424 Capital Announces Successful Exit of Reverba
PR Newswire
WAKEFIELD, Mass., Nov. 19, 2026
WAKEFIELD, Mass., Nov. 19, 2026 /PRNewswire/ -- 424 Capital ("424"), a lower middle market private equity firm focused on investing in tech-enabled services companies in the healthcare and energy transition sectors, today announced the successful exit of its investment in Reverba, a leading provider of patient and healthcare professional engagement solutions to the life sciences industry. Reverba was acquired in a strategic transaction. Terms of the transaction were not disclosed.
424 partnered with Reverba, formerly Health Perspectives Group, in 2021 with a vision to build upon the company's differentiated patient-engagement capabilities and create a broader platform serving pharmaceutical and biotechnology companies across the drug-development and commercialization lifecycle.
"Reverba represents the type of business we seek to build at 424 — one with a compelling mission and a differentiated market position," said Amit Nagdev, Partner at 424 Capital. "We are incredibly proud of what Cheryl and the entire Reverba team accomplished during our partnership. Together, we strengthened the organization, expanded its capabilities, and built a more strategic partner to some of the world's leading life sciences companies."
During 424's ownership, Reverba made significant investments in its leadership team, operating infrastructure, and commercial organization. Reverba also expanded its capabilities through the acquisition of Six Degrees Medical, adding medical communications and healthcare professional engagement capabilities, establishing an international presence, and extending the company's reach earlier into the drug-development lifecycle. The combination broadened Reverba's offering beyond its historical patient-engagement focus and positioned the company to support life sciences clients across both patient and healthcare professional audiences.
Throughout this evolution, Reverba remained focused on its core mission of bringing the patient voice into the development and commercialization of therapies and helping patients better understand their diseases, treatment options, and care journeys. As therapies become increasingly specialized and personalized, Reverba's work helps make complex science and treatments more understandable and meaningful to the people they are intended to serve.
"424 has been an incredibly supportive partner as we have evolved and expanded Reverba," said Cheryl Lubbert, CEO of Reverba. "Their team shared our conviction in the importance of our mission and invested alongside us in the people, capabilities, and infrastructure needed to serve our clients and their patients in more meaningful ways. We are proud of what we have built together and excited about Reverba's next chapter."
Baird served as the exclusive financial advisor to Reverba, and Whiteman Osterman & Hannah LLP as legal counsel.
About 424 Capital
424 Capital is a lower middle market private equity firm that partners with founders and management teams to accelerate the growth of tech-enabled services businesses. 424 takes an operationally intensive approach to investing, working alongside management teams to professionalize organizations, accelerate organic growth, execute strategic acquisitions, and build scaled market leaders. For more information, visit www.424capital.com.
About Reverba
Reverba is a global health engagement company that helps life sciences organizations connect with patients and healthcare professionals through meaningful, insight-driven engagement. The company partners with pharmaceutical and biotechnology organizations across the therapy lifecycle, helping bring the voices and experiences of patients and healthcare professionals into the development and commercialization of therapies.
Contact
Jennifer Mosto
jmosto@424capital.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/424-capital-announces-successful-exit-of-reverba-302946117.html
SOURCE 424 Capital
